Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT05245474 by Beijing Friendship Hospital, with a registry enrolment figure of 186 participants, started 2022-04-01 and due to reach its primary completion in 2024-03-01. Interventions recorded: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor). Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: pCR rate. Colorectal eligibility wording from the registry: "* biopsy diagnosed rectal adenocarcinoma, distal margin within 10cm to anal verge". Sites: China. No results are recorded here; the registry entry is the source.